CWAN Stock Recent News
CWAN LATEST HEADLINES
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics Holdings, Inc. (NYSE: CWAN). Under the terms of the proposed transaction, shareholders of Enfusion will receive $5.85 in cash and $5.40 in Clearwater Class A Common Stock for each share of Enfusion that they own. KSF is seeking to determine whether this consi.
NEW YORK , Jan. 13, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Enfusion, Inc. (NYSE: ENFN) and its board of directors concerning the proposed acquisition of the company by Clearwater Analytics (NYSE: CWAN). Stockholders will receive a mix of shares of Clearwater Analytics common stock and cash worth $11.25 for each share of Enfusion stock that they hold.
Enfusion +0.84 (+8.41%) Clearwater Analytics -1.48 (-5.47%)
Clearwater Analytics + Enfusion +0.76 (+7.61%)
Clearwater Analytics, a company developing accounting, compliance, and risk reporting tools for asset managers, said on Monday it has entered into a definitive agreement to acquire investment management platform Enfusion for $1.5 billion.
Clearwater Analytics has agreed to acquire investment management platform Enfusion in a $1.5 billion cash-and-stock deal, the companies said on Monday.
BOISE, Idaho & CHICAGO--(BUSINESS WIRE)--Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate E.
Clearwater Analytics (CWAN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SRDX and CWAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.